Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

NCT02887040 is registered in ClinicalTrials.gov with Burzynski Research Institute as lead sponsor.

NCT NCT02887040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02887040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma
Lead sponsor
Burzynski Research Institute
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
June 30, 2026
Enrollment
92 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain stem glioma